Trials / Withdrawn
WithdrawnNCT02973191
A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia
A Phase 2, Open-label, Multiple Cohort, Single-arm, Multi-center Trial to Determine the Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-cell Acute Lymphoblastic Leukemia.
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, multi-center, open-label, Phase 2 study to determine the efficacy and safety of JCAR015 in adult subjects with B-cell ALL. The study is divided into two sequential parts, Part A and Part B; subjects will be screened and will provide informed consent before initiating any study procedures in Part A of the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JCAR015 |
Timeline
- Start date
- 2016-12-20
- Primary completion
- 2019-06-25
- Completion
- 2021-01-24
- First posted
- 2016-11-25
- Last updated
- 2017-04-10
Locations
18 sites across 7 countries: Belgium, France, Germany, Italy, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT02973191. Inclusion in this directory is not an endorsement.